In patients with symptomatic severe aortic stenosis at intermediate or higher surgical risk, CoreValve or Evolut transcatheter aortic valve implantation (TAVI) was associated with a lower 5-year ...

There are two options to consider if you need to have your aortic valve replaced.

A minimalist strategy of local anesthesia without sedation may be as safe and feasible as a standard-of-care approach that includes conscious sedation for many patients undergoing transcatheter aortic ...

After receiving a green light earlier this year from the FDA, Medtronic has now collected a European approval for the latest version of its transcatheter aortic valve replacement implant. Compared to ...

Female patients with symptomatic, severe aortic stenosis who undergo TAVI with a balloon-expandable Sapien 3 or Sapien 3 Ultra valve (Edwards Lifesciences) see better 1-year outcomes than those ...

Edwards Lifesciences and Medtronic have been battling each other for half a dozen years (at least) over a heart valve patent, and recent news suggests Germany's District Court of Mannheim will favor ...

CHICAGO, IL—Five-year follow-up for patients with severe aortic stenosis and low surgical risk affirm the benefits of TAVI with a self-expanding, supra-annular valve compared with surgery, according ...

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, outcomes were similar among patients who had undergone transcatheter aortic-valve ...

Aug 1 (Reuters) - Medtronic Plc : * CoreValve Evolut R System TAVI to receive CE mark for intermediate risk aortic stenosis patients Source text for Eikon: Further company coverage: ...

A simpler alternative to open heart surgery is gaining popularity, but some find ​their new valves don’t last as long as they ...